The popular once-weekly Tirzepatide injection — widely used overseas for weight loss and developed by Eli Lily — is now available at our clinic.
Interested in the once- weekly weight loss injection? Enquire Now! to WhatsApp us and speak with our team directly.
Orforglipron is an investigational oral GLP-1 receptor agonist created by Eli Lilly as part of the advancing field of medical weight management. Unlike existing GLP-1 medications administered via once-weekly injections, Orforglipron is designed as a once-daily pill. This offers a potential non-injectable option for individuals who prefer daily oral therapy for appetite regulation, satiety enhancement and metabolic support.
As a small-molecule GLP-1 compound, Orforglipron activates pathways associated with hunger control, gastric-emptying delay and glucose balance. By delivering these effects through an oral route, the medication may broaden accessibility to supervised weight-loss programmes for patients who find injectable therapies less suitable or less convenient.
In a global Phase 2/3 study published on 20 November 2025, more than 1,500 adults across ten countries treated daily with Orforglipron at a 36 mg dose achieved an average weight reduction of approximately 10 percent over 72 weeks, compared with around 2 percent in the placebo group. The study also reported improvements in insulin sensitivity and lipid profiles. While these results are early, they highlight growing interest in oral GLP-1 therapy for obesity treatment.
Orforglipron is not yet approved for use in Singapore, as further Phase 3 trials and regulatory reviews are ongoing. If approved, it may become a significant addition to medically supervised weight-management options in the region.
At present, the only approved oral GLP-1 option in Singapore is Rybelsus. You may learn more about Rybelsus and other GLP-1 weight-loss medications at the following links:
Orforglipron is a small-molecule oral GLP-1 receptor agonist being developed by Eli Lilly for the treatment of obesity and metabolic disorders. It differs from traditional peptide-based GLP-1 medications because it is chemically structured to withstand digestion and be absorbed through the gastrointestinal tract, allowing for once-daily oral dosing without the need for injection.
As an emerging member of a new class of oral GLP-1 compounds, Orforglipron is designed to activate the same hormonal pathways involved in appetite regulation, satiety signalling and glucose balance, but through a tablet formulation rather than an injectable peptide. This small-molecule design is one of the key scientific distinctions that sets Orforglipron apart within the GLP-1 category.
The medication is currently undergoing advanced clinical studies to evaluate its pharmacology, metabolic impact and long-term tolerability. Researchers are also examining how its oral structure influences dose flexibility, treatment adherence and suitability for patients who may prefer tablet-based therapy over injectable regimens.
While Orforglipron remains under investigation and is not yet approved for public use, its development represents an important step in expanding the future range of GLP-1-based therapies available for medically supervised weight management.
Orforglipron works by activating the GLP-1 receptor, a key hormonal pathway involved in regulating appetite, satiety and metabolic balance. As an oral small-molecule GLP-1 agonist, it triggers physiological responses similar to naturally occurring incretin hormones, helping the body manage hunger and energy use more effectively.
One of its primary mechanisms is the enhancement of satiety signalling within the brain’s appetite-regulation centres. By increasing feelings of fullness after meals and reducing hunger between meals, Orforglipron helps lower overall calorie intake in a controlled and sustainable manner.
The medication also slows gastric emptying, allowing food to remain in the stomach for a longer period. This contributes to improved portion control, steadier post-meal glucose levels and reduced cravings. In addition, GLP-1 receptor activation supports healthier insulin response and glucose metabolism, which may benefit individuals with metabolic risk factors.
Unlike peptide-based GLP-1 injectables, Orforglipron delivers these effects through a daily oral dose. Its small-molecule structure enables intestinal absorption while still producing incretin-mediated metabolic activity. This design is being studied for its potential to provide consistent appetite regulation without the need for weekly injections.
Ongoing clinical research continues to evaluate how Orforglipron influences body composition, fat distribution, metabolic markers and long-term weight-loss stability. These findings will determine its eventual role within medically supervised obesity-management programmes once approved.
Orforglipron has demonstrated encouraging outcomes across multiple early- and mid-stage clinical studies designed to evaluate its effectiveness for weight reduction and metabolic improvement. These trials assess how daily oral activation of the GLP-1 receptor influences appetite regulation, energy intake and long-term weight trajectories in adults with obesity or overweight.
In a large international Phase 2/3 study published in November 2025, more than 1,500 participants across ten countries received Orforglipron at various daily doses for up to 72 weeks. Individuals treated with the 36 mg dose achieved an average body-weight reduction of roughly 10 percent, whereas participants in the placebo group experienced about a 2 percent reduction. This study also reported improvements in fasting glucose, insulin sensitivity, lipid markers and waist circumference, indicating a broader metabolic impact beyond weight loss alone.
Earlier dose-escalation studies further supported these findings, showing that higher doses of Orforglipron were associated with greater appetite reduction and more consistent post-meal glucose control. These trials also examined how different dose-titration schedules may help improve tolerability and minimise early gastrointestinal symptoms.
Safety and tolerability continue to be closely monitored in ongoing Phase 3 trials. The most commonly reported side effects include nausea, diarrhoea and reduced appetite, which were generally transient and lessened as the body adjusted to treatment. Researchers are also evaluating long-term outcomes such as cardiometabolic improvements, treatment adherence and sustained weight-loss stability over extended durations.
The results of these studies will guide regulatory decisions and determine whether Orforglipron will be approved as a future doctor-supervised weight-management option in Singapore.
Orforglipron is not yet available for prescription use in Singapore or in other markets. The medication is still undergoing Phase 3 clinical trials to evaluate long-term safety, metabolic outcomes and sustained weight-loss effects. As an investigational therapy, it has not received approval from major regulatory agencies such as the United States Food and Drug Administration (FDA) or Singapore’s Health Sciences Authority (HSA).
Eli Lilly is expected to proceed with regulatory submissions only after completing its late-stage studies. Based on current development timelines, Orforglipron is unlikely to be available in Singapore until 2026 or later. Final approval dates will depend on international regulatory reviews, trial outcomes and the company’s global launch strategy.
Patients in Singapore interested in medically supervised weight loss should rely only on approved and regulated treatments. Current GLP-1 options such as semaglutide and tirzepatide have established safety profiles and are legally available under doctor supervision. These medications support appetite regulation, improved glucose control and long-term metabolic management.
Unverified or grey-market versions of Orforglipron being sold online should be avoided, as they are unregulated, potentially unsafe and not medically endorsed. Individuals considering weight-loss medication should consult a licensed doctor for appropriate assessment, treatment planning and ongoing monitoring.
Orforglipron is a small-molecule oral GLP-1 receptor agonist being developed by Eli Lilly for the treatment of obesity and metabolic disorders. It differs from traditional peptide-based GLP-1 medications because it is chemically structured to withstand digestion and be absorbed through the gastrointestinal tract, allowing for once-daily oral dosing without the need for injection.
As an emerging member of a new class of oral GLP-1 compounds, Orforglipron is designed to activate the same hormonal pathways involved in appetite regulation, satiety signalling and glucose balance, but through a tablet formulation rather than an injectable peptide. This small-molecule design is one of the key scientific distinctions that sets Orforglipron apart within the GLP-1 category.
The medication is currently undergoing advanced clinical studies to evaluate its pharmacology, metabolic impact and long-term tolerability. Researchers are also examining how its oral structure influences dose flexibility, treatment adherence and suitability for patients who may prefer tablet-based therapy over injectable regimens.
While Orforglipron remains under investigation and is not yet approved for public use, its development represents an important step in expanding the future range of GLP-1-based therapies available for medically supervised weight management.
Researchers are investigating a range of potential benefits associated with Orforglipron as part of its ongoing clinical development. As an oral GLP-1 receptor agonist, Orforglipron is being studied for its ability to regulate appetite, improve metabolic markers and support sustained weight reduction through a once-daily pill format.
One of the primary areas of interest is appetite control. Early trial data suggests that Orforglipron may help reduce hunger signals and increase satiety after meals, contributing to lower calorie intake throughout the day. This mechanism is similar to injectable GLP-1 therapies but delivered through an oral small-molecule compound.
Another potential benefit under evaluation is improved glucose regulation. Activation of the GLP-1 receptor may help stabilise post-meal glucose levels, enhance insulin response and reduce glycaemic variability. These effects may be relevant for individuals with metabolic risk factors such as prediabetes or insulin resistance.
Researchers are also examining Orforglipron’s impact on metabolic health indicators, including lipid balance, blood pressure and waist circumference. Interim trial results have shown favourable changes in these markers, suggesting that the medication may offer broader cardiometabolic effects beyond weight loss alone.
The oral formulation itself is an important aspect of Orforglipron’s development. A once-daily pill may improve treatment accessibility for individuals who prefer oral medication over injections, potentially supporting better adherence in long-term weight-management programmes.
As clinical trials progress, additional data will clarify the full extent of Orforglipron’s metabolic effects, safety profile and suitability for chronic weight-management use once regulatory approval is granted.
As Orforglipron remains in the investigational phase, its safety profile continues to be evaluated through ongoing Phase 3 clinical trials. Early research suggests that the medication may share similar tolerability patterns with other GLP-1 receptor agonists, particularly with regard to gastrointestinal effects during the initial stages of treatment.
The most commonly reported side effects in early studies include nausea, decreased appetite, diarrhoea and abdominal discomfort. These symptoms were generally mild to moderate and tended to lessen as participants continued treatment and their bodies adjusted to the medication. This pattern is consistent with the class effects observed in other GLP-1 therapies used for weight management.
Some participants in clinical studies also reported transient vomiting, constipation and indigestion. These effects appeared to be dose-related, with higher doses more likely to trigger gastrointestinal symptoms. Researchers continue to assess how dose escalation schedules may help improve overall tolerability.
Beyond gastrointestinal effects, clinical trials are monitoring potential changes in heart rate, blood pressure and metabolic markers to identify any long-term risks. Laboratory assessments are also being conducted to evaluate kidney and liver function during extended treatment periods.
It is important to note that long-term safety data for Orforglipron is not yet available, as final Phase 3 results and regulatory reviews are still pending. Individuals considering weight-loss medication should consult a licensed medical practitioner to discuss approved options that have established safety profiles.
While Orforglipron is still under clinical investigation, several approved medical treatments are currently available in Singapore to support doctor-supervised weight loss. These therapies work through established metabolic pathways and are prescribed based on individual health profiles, treatment goals and response to medication.
GLP-1 receptor agonists remain one of the most effective pharmacological options for appetite regulation, improved satiety and long-term weight control. In Singapore, patients have access to a range of injectable and oral GLP-1 medications that have undergone regulatory review and have established safety data.
Injectable GLP-1 options include once-weekly semaglutide and tirzepatide, which help reduce calorie intake, stabilise glucose levels and support sustained weight reduction under medical supervision. For individuals who prefer a tablet-based approach, oral semaglutide is available as a daily medication with similar GLP-1–mediated metabolic benefits.
These medications are typically prescribed as part of a structured, medically supervised programme that includes regular monitoring, dose adjustments and ongoing review to ensure safe and effective treatment.
Patients may learn more about approved options at the following links:
Individuals interested in medically supervised weight loss can benefit from a personalised assessment by a licensed practitioner. A doctor will evaluate factors such as weight-history patterns, metabolic risk markers, medication suitability and potential contraindications before recommending an appropriate treatment plan. This ensures that any therapy selected aligns with clinical safety standards and long-term weight-management goals.
At Edwin Lim Medical Aesthetic Clinic, patients may consult Dr Edwin Lim to explore approved treatment options such as semaglutide, tirzepatide or oral GLP-1 medication, depending on their medical profile and treatment preferences. As new therapies like Orforglipron progress through clinical development, Dr Lim can also provide updates on future availability, emerging research data and how upcoming medications may fit into personalised treatment strategies once approved.
1. Individuals seeking professional guidance may schedule a consultation at:
Dr Edwin Lim
MBBS (Singapore), MRCS (Edinburgh), PgDip Practical Dermatology (Cardiff), MSc Practical Dermatology (Cardiff), Diploma in Aesthetic Medicine, (AAAM), Accredited by the Aesthetic Dermatology Educational Group (ADEG)
